Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risk of adverse pregnancy outcomes with Leflunomide exposure during early pregnancy in Quebec Pregnancy Cohort.

Trial Profile

Risk of adverse pregnancy outcomes with Leflunomide exposure during early pregnancy in Quebec Pregnancy Cohort.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Leflunomide (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 08 Dec 2017 Results assessing the risk of major congenital malformation, prematurity, low birth weight and spontaneous abortion associated with leflunomide exposure during pregnancy published in the Annals of the Rheumatic Diseases
    • 25 Sep 2017 New trial record
    • 30 Aug 2017 Results presented at the 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top